Pharmacia & Upjohn Company

Pfizer Corporation

Pharmacia & Upjohn

Saeeduddin Ahmed

Robert Clyde Marshall

Duncan Paul Taylor

Erik H F Wong

Robert McArthur

Lars Birgerson

Pasquale Cetera

Methods and compositions for treating humans suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or a condition where inhibiting reuptake of norepinephrine is a benefit are disclosed. The compositions comprise a compound having a pharmacological selectivity of serotonin (K)/norepinephrine (K) of at least about 5000. Examples of such compounds include reboxetine, and more preferably optically pure (S,S) enantiomer of reboxetine. The methods generally include administration of a therapeutic amount of such compositions. Also disclosed are preparations of a medicament from the composition, and uses of the composition in a manufacture of the medicament to treat a human suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or condition.

Highly selective norepinephrine reuptake inhibitors and methods of using the same

Disclosed herein are methods of treating an individual suffering from, chronic fatigue syndrome. The methods generally include administration of a therapeutic amount of racemic reboxetine, or a pharmaceutically acceptable salt thereof, to the individual.

Method of treating chronic fatigue syndrome

Disclosed herein are methods of treating an individual suffering from peripheral neuropathy. The methods generally include administration of a therapeutic amount of optically pure (S,S) reboxetine, or a pharmaceutically acceptable salt thereof. Embodiments of these methods can diminish adverse side effects.

Method of treating peripheral neuropathy

Disclosed herein are methods of treating an individual suffering from, chronic fatigue syndrome. The methods generally include administration of a therapeutic amount of optically pure (S,S) reboxetine, or a pharmaceutically acceptable salt thereof, to the individual. Embodiments of these methods can diminish adverse side effects.

Disclosed herein are methods of treating an individual suffering from peripheral neuropathy. The methods generally include administration of a therapeutic amount of racemic reboxetine, or a pharmaceutically acceptable salt thereof, to the individual.

Method of treating incontinence

Methods and compositions for treating humans suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or a condition where inhibiting reuptake of norepinephrine is a benefit are disclosed. The compositions comprise a compound having a pharmacological selectivity of serotonin (K )/norepinephrine (K ) of at least about 5000. Examples of such compounds include reboxetine, and more preferably optically pure (S,S) enantiomer of reboxetine. The methods generally include administration of a therapeutic amount of such compositions. Also disclosed are preparations of a medicament from the composition, and uses of the composition in a manufacture of the medicament to treat a human suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or condition.

Method of treating chronic pain

Methods for treating humans suffering from, migraine headaches by inhibiting reuptake of norepinephrine are disclosed. The methods comprise a compound having a pharmacological selectivity of serotonin (K )/norepinephrine (K ) of at least about 5000. Examples of such compounds include reboxetine, and more preferably optically pure (S,S) enantiomer of reboxetine.

Method of treating migraine headaches with a highly selective noreoinephrine reuptake inhibitor

This application relates to methods for treating humans suffering from, fibromyalgia or other somatoform disorders where inhibiting reuptake of norepinephrine is a benefit. The methods comprise a compound having a pharmacological selectivity of serotonin (K )/norepinephrine (K ) of at least about 5000. Examples of such compounds include reboxetine, and more preferably optically pure (S,S) enantiomer of reboxetine.

Method of treating or preventing fibromyalgia and other somatoform disorders with a highly selective norepinephrine reuptake inhibitor

Methods and compositions for treating humans suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or a condition where inhibiting reuptake of norepinephrine is a benefit are disclosed. The methods comprise administering the optically pure (S,S) enantiomer of reboxetine. The methods generally include administration of a therapeutic amount of such compositions. Also disclosed are preparations of a medicament from the composition, and uses of the composition in a manufacture of the medicament to treat a human suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or condition.

Growing community of inventors

Plainfield, IN, United States of America

Saeeduddin Ahmed